ClearLight Closes Lab Services and Offers Expert Consulting Services Learn More

ClearLight Biotechnologies Expertise

About Us

Researchers who work with us See More Biology

Our Mission

ClearLight empowers researchers to see more biology within the tissue microenvironment. We are developing technologies to improve diagnostic, prognostic, and predictive treatment of disease so we can all live healthier lives.

Fast Facts

  • Founded in 2015 by Karl Deisseroth MD, PhD
  • Early stage private company backed by Wiegers and affiliates, Pivotal and KESA Partners
  • Experts at CLARITY Tissue Processing, thick tissue antibody staining, and Tru3D tissue analysis
  • Provides research use only lab services to pharmaceutical, biotechnology and academic researchers
  • Developing next-generation tissue processing and image analysis platform to facilitate 3D analysis of preclinical and clinical models of disease
Karl Deisseroth, MD, PhD Founder & Scientific Advisor

Over a period of twelve years, his laboratory created and developed optogenetics, hydrogel-tissue chemistry (beginning with CLARITY), and a broad range of supportive and enabling methods. He also has employed his technologies to discover the neural cell types and connections that cause adaptive and maladaptive behaviors, and has disseminated the technologies to thousands of laboratories around the world.

Karl Deisseroth, MD, PhD

Founder & Scientific Advisor

Karl Deisseroth is the D.H. Chen Professor of Bioengineering and of Psychiatry and Behavioral Sciences at Stanford University, and Investigator of the Howard Hughes Medical Institute. He received his undergraduate degree from Harvard, his PhD and MD from Stanford; he also completed postdoctoral training, a medical internship, and an adult psychiatry residency at Stanford. He is board-certified by the American Board of Psychiatry and Neurology. He also continues to be a practicing psychiatrist at Stanford with specialization in affective disorders and autism-spectrum disease, employing medications along with neural stimulation.

For his discoveries, Deisseroth has received the NIH Director's Pioneer Award (2005), the Zuelch Prize (2012), the PerlPrize (2012), the BRAIN prize (2013), the Pasarow Prize (2013), the Breakthrough Prize (2015) the BBVA Award (2016), the Massry Prize (2016) and the Harvey Prize from the Technion/Israel (2017), and among other honors, was the sole recipient for optogenetics of the 2010 Koetser Prize, the 2010 Nakasone Prize, the 2011 Alden Spencer Prize, the 2013 Richard Lounsbery Prize, the 2014 Dickson Prize in Science, the 2015 Keio Prize, the 2015 Lurie Prize, the 2015 Albany Prize, the 2015 Dickson Prize in Medicine, the 2017 Redelsheimer Prize, the 2017 Fresenius Prize, the 2017 NOMIS Distinguished Scientist Award, the 2018 Eisenberg Prize, and the 2018 Kyoto Prize. He was selected a Howard Hughes Medical Institute Investigator in 2013, and was elected to the US National Academy of Medicine in 2010 and to the US National Academy of Sciences in 2012.

Learn About ClearLight Biotechnologies Expertise

ClearLight Biotechnologies expertise includes CLARITY Tissue Clearing, 3D Immunohistochemistry, and Tru3D Image Analysis. See our Tissue Clearing Comparison to see how CLARITY + Tru3D stack up to other tissue clearing protocols.

Tissue Clearing Using CLARITY method - ClearLight Biotechnologies

CLARITY Tissue Clearing

CLARITY Tissue Clearing

Need to know more about CLARITY Tissue Clearing? Visit the CLARITY tissue clearing page to learn the background and specific steps in the ClearLight CLARITY Tissue Clearing Process. Download the CLARITY Tissue Clearing Infographic.

Human Lung Carcinoma: CLARITY Tissue Cleared - Immunostained - Imaged - DAPI (blue), pan-cadherin (green), CD8 (yellow), α-SMA (red)



ClearLight offers antibody-based immunostaining or labeling for many nucleic acids (RNA/DNA) to highlight specific structures in the clarified sample. Multiplexed immunofluorescence staining enables advanced Tru3D™ tissue analysis.

See for Yourself

See for Yourself

Clearing Comparison

Considering the CLARITY technique alongside other tissue clearing protocols? There are many to choose from. We evaluated four in this head-to-head comparison of tissue clearing protocols, CLARITY, CUBIC, iDISCO, and Visikol® HISTO™.

2019 AACR Poster

Multi-sample automation of CLARITY technology for processing 3D volumes of tissue. Sharla White, PhD presented poster #4690 at AACR Annual Meeting 2019, Atlanta.

Award Winning Breast Cancer Study

“Three-dimensional Imaging and Quantitative Analysis in CLARITY Processed Breast Cancer Tissues,” awarded as one of the top 100 downloaded cancer papers.

Building a Collaborative Future

ClearLight Biotechnologies (formerly ClearLight Diagnostics, LLC) was founded in 2015 by Karl Deisseroth MD, PhD, the inventor of CLARITY, Optogenetics, and STARmap technologies. It is an early stage company focused on developing automated instrumentation and associated reagents to simplify and expedite non-destructive 3D tissue analysis to facilitate preclinical and clinical research applications. The platform will enable an end-to-end solution for 3D analysis of preclinical and clinical models of disease.

Enter the MicroEnvironment

Imagine non-destructive tissue processing and digital spatial image analysis in 3D to facilitate your pre-clinical and clinical research studies

Imagine a way to illuminate your tissue microenvironment in a 3D volume

Imagine automating this process and integrating it into your normal tissue processing work flow

This is the capability we are building at ClearLight Biotechnologies

ClearLight Biotechnologies’ automated instrumentation platform study is featured as the 4th news story in Clinical Lab Products’ Prime email newsletter and on Clinical Lab Products’ magazine.

Study Shows Promise for Revolutionizing Spatial Tumor Analysis.

4 Major Platform Components

Multi-sample 3D Tissue Processor
Multi-color/ sample 3D Imaging
Custom 3D Image Analysis Software
Development of Key Biomarker Panels


Could be applied to any application that relies
on 2D thin section FFPE analysis


Near Term

Research Use Only (RUO) Service Model
and Limited Beta instruments in field

Preclinical/clinical drug development, exploratory technology inclusion in clinical trials


RUO instrument in field, Companion Diagnostics, LDT (ClearLight Biotechnologies has exclusive rights to diagnostic, prognostic, predictive applications)

Engage with ClearLight Biotechnologies

Collaborate with Us

We are building something special. We invite you to coordinate with our scientific staff. Talk to a member of our science team about research alignment. See how your team can leverage ClearLight’s expertise to help achieve its research objectives.

Work Here

Be part of our team developing a revolutionary approach to non-destructive tissue processing and 3D digital image analysis. Visit careers to see opportunities. Follow our LinkedIn page and engage with us on FacebookTwitter, and YouTube.

Join the Creating Cures Community

We applaud the research community and their involvement in the drug discovery and development process. These are the modern heroes who will create the cures of tomorrow for the diseases that impact human potential and decrease lifespan. Join us.

Subscribe to Newsletter

Analysis can be performed for select biomarkers, please contact us to find out if your target of interest is one of them. Imaging is currently performed on select fields of view instead of the entire sample.

Submission Guidelines

Tissue Sample Requirements: